Historique
Bulletin de Périodique
Addiction , Vol.119, n°4 - April 2024
Paru le :
01/04/2024
Article en page(s) :
601-792
Langue(s) :
Anglais
Note de contenu :
CONTENTS:
- Clinical considerations for the management of xylazine overdoses and xylazine-related wounds [Editorial]. Sue K.L., Hawk K., p. 606-608.
- Does nitrous oxide addiction exist? An evaluation of the evidence for the presence and prevalence of substance use disorder symptoms in recreational nitrous oxide users [Addiction opinion and debate]. Back S., Kroon E., Colyer-Patel K., Cousijn J., p. 609-618.
- It is time to take nitrous oxide seriously without waiting for more evidence of harms. Allan J., Cameron J., Simpson H., Kor K., p. 619-620.
- Nitrous oxide: A difficult case for classification as an addictive substance. Brunt T.M., p. 621-622.
- Nitrous oxide: The label 'potentially addictive' may do more harm than good. Winstock A.R., p. 623-624.
- Yes, nitrous oxide addiction undeniably exists! Victorri-Vigneau C., Grall Bronnec M., p. 625-626.
- Nitrous oxide addiction or not, action is needed. A response to commentaries. Back S., Kroon E., Colyer-Patel K., Cousijn J., p. 627-628.
- Effectiveness of culturally tailoring smoking cessation interventions for reducing or quitting combustible tobacco: A systematic review and meta-analyses. Leinberger-Jabari A., Golob M.M., Lindson N., Hartmann-Boyce J., p. 629-648.
- Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: A systematic review and meta-analysis. De Santi O., Orellana M., Di Niro C.A., Greco V., p. 649-663.
- Do medications increase the efficacy of digital interventions for smoking cessation? Secondary results from the iCanQuit randomized trial. Bricker J.B., Santiago-Torres M., Mull K.E., Sullivan B.M., David S.P., Schmitz J., et al., p. 664-676.
- Health and economic burden of low back pain and rheumatoid arthritis attributable to smoking in 192 countries and territories in 2019. Chen N., Fong D.Y.T., Wong J.Y.H., p. 677-685.
- Smoking, vaping and drinking: A qualitative analysis of Aotearoa New Zealand young adults who tried e-cigarettes to stop smoking tobacco. Blank M.L., Hoek J., p. 686-695.
- Distributions of alcohol use and alcohol-caused death and disability in Canada: Defining alcohol harm density functions and new perspectives on the prevention paradox. Sherk A., Churchill S., Cukier S., Grant S.C., Shield K., Stockwell T., p. 696-705.
- Disentangling the contributions of alcohol use disorder and alcohol-related liver disease towards dementia: A population-based cohort study. Zhao S., Widman L., Hagström H., Shang Y., p. 706-716.
- Efficacy and safety of short-term edaravone or nerve growth factor add-on therapy for alcohol-related brain damage: A multi-centre randomised control trial. Wang H., Liu L., Zhou X., Guan Y., Li Y., Chen P., et al., p. 717-729.
- Health-care resource use among patients who use illicit opioids in England, 2010-20: A descriptive matched cohort study. van Hest N., Brothers T.D., Williamson A., Lewer D., p. 730-740.
- An on-line school-based substance use harm reduction programme: The Illicit Project randomized controlled trial results. Debenham J., Birrell L., Champion K.E., Newton N., p. 741-752.
- Longitudinal trajectories of substance use disorder treatment use: A latent class growth analysis using a national cohort in Chile. Borquez I., Cerda M., Gonzalez-Santa Cruz A., Krawczyk N., Castillo-Carniglia A., p. 753-765.
- Performance of International Classification of Disease-10 codes in detecting emergency department patients with opioid misuse. Chhabra N., Smith D., Pachwicewicz P., Lin Y., Bhalla S., Maloney C.M., et al., p. 766-771.
- Enhanced cannabis timeline followback (EC-TLFB): Comprehensive assessment of cannabis use including standard THC units and validation through biological measures. Petrilli K., Lawn W., Lees R., Mokrysz C., Borissova A., Ofori S., et al., p. 772-783.
- Commentary on Petrilli et al.: Assessing cannabis use in real-world settings - advances using standard THC units. Compton W., Weiss S., p. 784-785.
- Do we need clinical trials of high dose stimulant agonist treatment for stimulant use disorders? Hall W., Darke S., Farrell M., p. 786-787.
- Response to Hall et al.: Prescription psychostimulants for amphetamine-type stimulant use disorder - acknowledging challenges but not giving up on its potential cost-effectiveness. Sharafi H., Jutras-Aswad D., p. 788-789.
- Clinical considerations for the management of xylazine overdoses and xylazine-related wounds [Editorial]. Sue K.L., Hawk K., p. 606-608.
- Does nitrous oxide addiction exist? An evaluation of the evidence for the presence and prevalence of substance use disorder symptoms in recreational nitrous oxide users [Addiction opinion and debate]. Back S., Kroon E., Colyer-Patel K., Cousijn J., p. 609-618.
- It is time to take nitrous oxide seriously without waiting for more evidence of harms. Allan J., Cameron J., Simpson H., Kor K., p. 619-620.
- Nitrous oxide: A difficult case for classification as an addictive substance. Brunt T.M., p. 621-622.
- Nitrous oxide: The label 'potentially addictive' may do more harm than good. Winstock A.R., p. 623-624.
- Yes, nitrous oxide addiction undeniably exists! Victorri-Vigneau C., Grall Bronnec M., p. 625-626.
- Nitrous oxide addiction or not, action is needed. A response to commentaries. Back S., Kroon E., Colyer-Patel K., Cousijn J., p. 627-628.
- Effectiveness of culturally tailoring smoking cessation interventions for reducing or quitting combustible tobacco: A systematic review and meta-analyses. Leinberger-Jabari A., Golob M.M., Lindson N., Hartmann-Boyce J., p. 629-648.
- Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: A systematic review and meta-analysis. De Santi O., Orellana M., Di Niro C.A., Greco V., p. 649-663.
- Do medications increase the efficacy of digital interventions for smoking cessation? Secondary results from the iCanQuit randomized trial. Bricker J.B., Santiago-Torres M., Mull K.E., Sullivan B.M., David S.P., Schmitz J., et al., p. 664-676.
- Health and economic burden of low back pain and rheumatoid arthritis attributable to smoking in 192 countries and territories in 2019. Chen N., Fong D.Y.T., Wong J.Y.H., p. 677-685.
- Smoking, vaping and drinking: A qualitative analysis of Aotearoa New Zealand young adults who tried e-cigarettes to stop smoking tobacco. Blank M.L., Hoek J., p. 686-695.
- Distributions of alcohol use and alcohol-caused death and disability in Canada: Defining alcohol harm density functions and new perspectives on the prevention paradox. Sherk A., Churchill S., Cukier S., Grant S.C., Shield K., Stockwell T., p. 696-705.
- Disentangling the contributions of alcohol use disorder and alcohol-related liver disease towards dementia: A population-based cohort study. Zhao S., Widman L., Hagström H., Shang Y., p. 706-716.
- Efficacy and safety of short-term edaravone or nerve growth factor add-on therapy for alcohol-related brain damage: A multi-centre randomised control trial. Wang H., Liu L., Zhou X., Guan Y., Li Y., Chen P., et al., p. 717-729.
- Health-care resource use among patients who use illicit opioids in England, 2010-20: A descriptive matched cohort study. van Hest N., Brothers T.D., Williamson A., Lewer D., p. 730-740.
- An on-line school-based substance use harm reduction programme: The Illicit Project randomized controlled trial results. Debenham J., Birrell L., Champion K.E., Newton N., p. 741-752.
- Longitudinal trajectories of substance use disorder treatment use: A latent class growth analysis using a national cohort in Chile. Borquez I., Cerda M., Gonzalez-Santa Cruz A., Krawczyk N., Castillo-Carniglia A., p. 753-765.
- Performance of International Classification of Disease-10 codes in detecting emergency department patients with opioid misuse. Chhabra N., Smith D., Pachwicewicz P., Lin Y., Bhalla S., Maloney C.M., et al., p. 766-771.
- Enhanced cannabis timeline followback (EC-TLFB): Comprehensive assessment of cannabis use including standard THC units and validation through biological measures. Petrilli K., Lawn W., Lees R., Mokrysz C., Borissova A., Ofori S., et al., p. 772-783.
- Commentary on Petrilli et al.: Assessing cannabis use in real-world settings - advances using standard THC units. Compton W., Weiss S., p. 784-785.
- Do we need clinical trials of high dose stimulant agonist treatment for stimulant use disorders? Hall W., Darke S., Farrell M., p. 786-787.
- Response to Hall et al.: Prescription psychostimulants for amphetamine-type stimulant use disorder - acknowledging challenges but not giving up on its potential cost-effectiveness. Sharafi H., Jutras-Aswad D., p. 788-789.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |
Dépouillements
Ajouter le résultat à votre sélection![Clinical considerations for the management of xylazine overdoses and xylazine-related wounds [Editorial]](https://bdoc.ofdt.fr/img_cache/pmb_ofdt_record_86901.webp)
This editorial reviews literature on xylazine as well as major clinical considerations for treatment and management of suspected xylazine-involved overdoses and xylazine-related wounds. The clinical presentation and management of xylazine overdo[...]
S. BACK ;
E. KROON ;
K. COLYER-PATEL ;
J. COUSIJN
|
2024
Dans Addiction (Vol.119, n°4, April 2024) Article : Périodique
Dans Addiction (Vol.119, n°4, April 2024) Article : Périodique
BACKGROUND: Prevalence of nitrous oxide (N2O) use appears to be increasing in numerous countries worldwide, and excessive use has been associated with physical and mental problems. Because there currently is no consensus whether N2O has addictiv[...]
N. CHHABRA ;
D. SMITH ;
P. PACHWICEWICZ ;
Y. LIN ;
S. BHALLA ;
C. M. MALONEY ;
M. BLUE ;
P. LEE ;
B. SHARMA ;
M. AFSHAR ;
N. S. KARNIK
|
2024
Dans Addiction (Vol.119, n°4, April 2024) Article : Périodique
Dans Addiction (Vol.119, n°4, April 2024) Article : Périodique
BACKGROUND AND AIMS: Accurate case discovery is critical for disease surveillance, resource allocation and research. International Classification of Disease (ICD) diagnosis codes are commonly used for this purpose. We aimed to determine the sens[...]
K. PETRILLI ;
W. LAWN ;
R. LEES ;
C. MOKRYSZ ;
A. BORISSOVA ;
S. OFORI ;
K. TRINCI ;
R. DOS SANTOS ;
H. LEITCH ;
S. SONI ;
L. A. HINES ;
V. LORENZETTI ;
H. V. CURRAN ;
T. P. FREEMAN
|
2024
Dans Addiction (Vol.119, n°4, April 2024) Article : Périodique
Dans Addiction (Vol.119, n°4, April 2024) Article : Périodique
AIMS: The aims of this study were to present an enhanced cannabis timeline followback (EC-TLFB) enabling comprehensive assessment of cannabis use measures, including standard tetrahydrocannabinol (THC) units, and to validate these against object[...]